Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First in Human, Multicenter, Open-Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and RP2D of ABBV-184 in Subjects With Previously Treated Cancers

NCT04272203 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04272203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04272203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First in Human, Multicenter, Open-Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and RP2D of ABBV-184 in Subjects With Previously Treated Cancers
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
May 5, 2020
Completion date
June 27, 2022
Enrollment
14 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), cancer, non small cell lung cancer